Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYSTONE-003: Pembrolizumab + Chemo in AEG
NCT04813523Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Apr 2021
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in adenocarcinoma of the esophagogastric junction (AEG), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
03
Conditions
adenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT04813523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04813523.